Crinetics Pharmaceuticals, Inc. Debt Securities, Trading, Amortized Cost
Crinetics Pharmaceuticals, Inc. (CRNX) had Debt Securities, Trading, Amortized Cost of $1.15 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:TradingSecuritiesDebtAmortizedCost · last filed 2026-08-03
- 2026-06-30: Debt Securities, Trading, Amortized Cost $1.15B.
- 2026-03-31: Debt Securities, Trading, Amortized Cost $1.18B.
- 2025-12-31: Debt Securities, Trading, Amortized Cost $924.32M.
- 2025-09-30: Debt Securities, Trading, Amortized Cost $979.15M.
| Period end | Debt Securities, Trading, Amortized Cost |
|---|---|
| 2026-06-30 | $1.15B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.18B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $924.32M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $979.15M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.14B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.18B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.09B 10-K · filed 2026-02-26 |
| 2023-12-31 | $502.68M 10-K · filed 2025-02-27 |
| 2022-12-31 | $305.68M 10-K · filed 2024-02-28 |